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1. Introduction 
1.1 Incidence and costs 
UTIs are a major source of morbidity and associated healthcare costs in the United States 
(US). Community-acquired UTIs largely affect women of reproductive age, with 11% of 
women experiencing infections each year, one-third of women having an infection by the 
age of 26, and 60% experiencing at least one infection during their lifetime (Foxman et al., 
2000). In 1997, the last year for which epidemiological data is available, these infections 
resulted in 7 million physician office visits and 1 million emergency room visits (Foxman, 
2002). Treatment of these infections cost $1.6 billion in 1995 (Foxman et al., 2000), which is 
the equivalent of $2.2 billion in inflation-adjusted 2009 dollars. UTIs are also a major health 
problem for hospitalized patients, especially those undergoing long-term catheterization. 
Catheter-associated UTIs account for >40% of nosocomial infections, with over 1 million 
cases per year at a cost of $451 million (Jacobsen et al., 2008).  
1.2 Diagnosis 
UTIs are defined clinically by the presence of a significant level of bacteria in the urine (i.e. 
bacteriuria). Guidelines vary, but typically a pure culture of between 104-106 colony forming 
units (CFUs)/milliliter (mL) of urine is indicative of a UTI. Patient symptoms are painful, 
urgent and frequent urination, along with malodorous and/or cloudy urine. Signs of 
infection include the presence of blood (hematuria) or white blood cells (pyuria) in urine. 
UTIs comprise a spectrum of diseases of varying severity, with different outcomes and 
treatment guidelines. Asymptomatic infections are referred to as asymptomatic bacteriuria 
(ABU), whereas symptomatic infections are classified as either cystitis if they are confined to 
the bladder or pyelonephritis if the infection has spread to the kidneys. Due the absence of 
symptoms, ABU is often only discovered through a positive urine culture, and does not 
require treatment unless risk factors for complication are present (e.g. pregnancy, kidney 
transplantation). Most catheter-associated nosocomial UTIs can be categorized as ABU, 
since the presence of a urinary catheter obscures patient symptoms. Cystitis is normally 
treated on an out-patient basis with oral antimicrobial therapy, although recurrence is a 
major problem, with 27% of patients experiencing another episode within 6 months and 44% 
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experiencing another episode within 1 year (Foxman, 1990, Ikaheimo et al., 1996). In addition 
to the symptoms of cystitis, pyelonephritis is characterized by fever, flank pain and 
vomiting. Pyelonephritis is a serious and potentially life-threatening condition that 
frequently results in hospitalization—nearly 200,000 such cases in were reported in the US 
in 1997 (Foxman et al., 2003). Pyelonephritis patients are at very high risk of developing 
sepsis (i.e. urosepsis), and 25% of all sepsis cases originate from a UTI (Wagenlehner et al., 
2008).  
1.3 Etiology 
The source of UTI pathogens is generally considered to be the patient’s own flora. UTIs are 
preceded by colonization of the vagina and periurethral area by uropathogens from the GI 
tract (Hilbert, 2011). Women are much more susceptible than men to community-acquired 
UTIs, in part, due to the female anatomy in that a much shorter urethra allows pathogens 
easier access to the bladder. Uropathogenic Escherichia coli (UPEC) is responsible for >80% of 
community-acquired UTIs, with most other infections caused by Staphylococcus 
saprophyticus, Klebsiella pneumoniae, Proteus mirabilis and Enterococcus faecalis (Ronald, 2003). 
UPEC is the cause of between one-third and one-half of all nosocomial UTIs, which in 
addition to the previously mentioned uropathogens, are also caused by Enterobacter spp., 
Pseudomonas aeruginosa, Group B streptococci and fungal pathogens (e.g. Candida spp.) 
(Mathai et al., 2001, Gordon & Jones, 2003, Hidron et al., 2008). Eighty percent of nosocomial 
UTIs are catheter-associated, as insertion of the catheter introduces fecal microbes and 
genital flora into the urinary tract (Jacobsen et al., 2008). 
2. Treatment 
2.1 Community-acquired UTIs 
Community-acquired symptomatic UTIs are treated with empirical antimicrobial therapy 
upon diagnosis based on patient symptoms. Urine cultures are recommended for 
complicated and recurrent cases, and may be performed for uncomplicated cases, although 
physician guidelines vary. Since treatment will precede identification of the pathogen, local 
trends for antibiotic resistance must be accounted for. The recommended first-line antibiotic 
therapy for cystitis is either 100 milligrams (mg) of nitrofurantoin per day for 5 days or 160 
mg-800 mg of trimethoprim-sulfamethoxazole (SXT) per day for 3 days. Nitrofurantoin 
should be avoided if pyelonephritis is suspected, as this drug only reaches an effective 
concentration in the bladder. SXT should be avoided if resistance in the area is >20% or if 
the patient has been treated with this antibiotic in the last three months. Another option for 
treatment is Pivmecillinam (400 mg daily for 3-7 days), but this drug is not approved for use 
in North America and some European countries. Fosfomycin (3 gram single dose) can also 
be used, but some studies suggest it is less effective than nitrofurantoin or SXT. Although 
amoxicillin and ampicillin should be avoided due to endemic resistance, 3-7 day courses of 
the -lactam--lactamase inhibitor combination amoxicillin-clavulanic acid, as well as 
cephalosporins such as cefaclor, cefdinir and cefpodoxime proxetil, may be used. However, 
they exhibit less effectiveness and are associated with more adverse effects than the 
recommended front-line therapies (nitrofurantoin and SXT). Fluoroquinolones (e.g. 
ciprofloxacin, ofloxacin and levofloxacin) are highly effective in 3-day courses, resistance is 
minimal and they are well-tolerated, but are only recommended as second-line therapies as 
they are highly useful for more serious infections and their judicious use will delay the rise 
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of resistance. Pyelonephritis is a much more serious conditions, often requiring 
hospitalization and paranteral administration of antibiotics—either ceftriaxone (400 mg) or a 
consolidated twenty-four hour dose (i.e. 7 mg drug/kg body weight) of an aminoglycoside 
(gentaminicin or tobramycin), in addition to oral ciprofloxacin (Gupta et al., 2011). 
2.2 Pregnant patients 
Although pregnant women are not at an increased risk for UTIs in general, they are more 
likely to develop pyelonephritis than non-pregnant women. Approximately 4-6% of both 
pregnant and non-pregnant women exhibit ABU. For otherwise healthy non-pregnant 
women, there is no need for treatment. However, if ABU is left untreated during pregnancy,  
20-40% of these women will develop pyelonephritis, often during the third trimester 
(Macejko & Schaeffer, 2007). As a consequence, The American College of Obstetricians and 
Gynecologists recommends screening for ABU in all pregnant women at sixteen weeks of 
gestation (Millar & Cox, 1997), and patients with positive cultures should be treated. The 
most important consideration in treatment is that it must be safe for both mother and fetus. 
Therefore, fluoroquinolones and trimethoprim should not be used, as they are assigned to 
the US Food and Drug Administration (FDA) pregnancy risk “C” category (gestational risk 
in animal studies and no adequate human studies performed). As with non-pregnant 
patients, nitrofurantoin can be used as a front-line therapy. As noted previously, 
nitrofurantoin is not recommended for treatment of pyelonephritis due to poor tissue 
penetration. Patients should have a follow-up urine culture one week later to determine if 
treatment was successful, as 20-30% of patients will require additional treatment. In 
addition, up to one-third of pregnant women will suffer a recurrent infection during 
pregnancy. Therefore, after the initial episode, either administration of prophylactic 
antimicrobial therapy (50-100 mg of nitrofurantoin nightly) or frequent urine cultures 
should be performed throughout the pregnancy (Macejko & Schaeffer, 2007). Any pregnant 
patient who develops pyelonephritis should be admitted and treated with paranteral 
antimicrobial therapy (see above). Complications of pyelonephritis during pregnancy 
include low fetal birth weight and neonatal death, as well as maternal anemia, hypertension, 
renal failure and sepsis. 
2.3 Catheter-associated UTIs 
Nosocomial UTIs are usually associated with catheterization, and asymptomatic infections 
are not normally treated unless additional complications are present. For symptomatic 
patients, the recommended procedure is replacement of the catheter combined with a 7-14 
days of treatment with an agent to which the pathogen is susceptible (e.g. SXT). Specifically, 
it has been found that a 5-day course of levofloxacin (oral or paranteral) is an appropriate 
treatment for patients who are not severely ill. Unlike community-acquired UTIs, culturing 
of a urine sample to identify the uropathogen and determination of antimicrobial 
sensitivities is recommended prior to treatment, due to the diversity of nosocomial 
uropathogens and high rates of resistance (Hooton et al., 2010).  
3. Antimicrobial resistance 
3.1 Uropathogenic E. coli (UPEC) 
3.1.1 -lactam antibiotics 
-lactams antibiotics are the oldest and most broadly used class of antibiotics. They exert a 
bactericidal effect by inhibiting bacterial cell wall synthesis and are administered both orally 
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and parenterally to treat a wide variety of bacterial infections. These antibiotics fall into 
three major structural categories—penicillins, cephalosporins and carbapenems. Penicillins, 
such as ampicillin and amoxicillin, were used previously as front-line therapies for UTIs. 
Resistance to these agents is mediated by -lactamases which degrade them, and these 
enzymes play an important role in antibiotic-refractory UTIs. The TEM, SHV and OXA 
classes of -lactamases hydrolyze penicillin -lactam antibiotics (e.g. amoxicillin) and are 
widely distributed among UPEC (Simpson et al., 1980), resulting in 38-48% of these isolates 
being ampicillin-resistant (Schito et al., 2009, Zhanel et al., 2006). The genes encoding these 
-lactamases are usually found on plasmids that are horizontally transferred between 
bacteria. Penicillin -lactam resistance can be overcome by combining the penicillin -lactam 
with a -lactamase inhibitor, such as ampicillin-sulbactam, amoxicillin-clavulanic acid or 
piperacillin-tazobactam. However, inhibitor-resistant TEM -lactamases have evolved, 
leading to emerging UPEC resistance—the Antimicrobial Resistance Epidemiological 
Survey (ARESC) of nine European countries and Brazil collected 2,315 UPEC isolates and 
found that 3.8% were resistant to amoxicillin-clavulanic acid (Schito et al., 2009). Similarly, 
the  SENTRY antimicrobial resistance surveillance program analyzed 1,316 nosocomial 
UPEC isolates in North America, Latin America and Europe and found 5% resistance to this 
combination (Gordon & Jones, 2003). Mutant TEM and SHV -lactamases have emerged that 
hydrolyze not only penicillins but also third-generation extended-spectrum cephalosporin 
-lactam antibiotics (e.g. ceftriaxone). These enzymes are referred to as extended-spectrum 
-lactamases (ESBLs). UPEC resistant to cerufoxime, and therefore expressing ESBLs, are 
responsible for 2.4% of community-acquired infections and 4% of nosocomial infections 
(Schito et al., 2009, Gordon & Jones, 2003). In addition, the US National Healthcare Safety 
Network analyzed 2,009 UPEC isolates from catheter-associated UTIs and found that 5.5% 
of isolates expressed ESBLs (defined by resistance to ceftriaxone or ceftazidime) (Hidron et 
al., 2008). Another class of -lactamases is CTX-M, which originated by horizontal transfer of 
a chromosomal -lactamase gene from the non-pathogenic genus Kluyvera. The epidemic 
UPEC clone O25:H4-ST131 encodes CTX-M-15, rendering it cephalosporin-resistant 
(Nicolas-Chanoine et al., 2008). The most recent evolution in -lactam resistance is the 
emergence of carbapenemases, enzymes that hydrolyze carbapenem of -lactam antibiotics, 
which are resistant to degradation by other ESBLs. Carbapenemases are already a problem 
among catheter-associated UTIs, with 4% of isolates resistant to imipenem, meropenem or 
ertapenem (Hidron et al., 2008). In addition,  the New Delhi metallo---lactamase-1 (NDM-
1) carbapenemase, has been identified in a O25:H4-ST131 UPEC isolate (Peirano et al., 2011). 
Although -lactam--lactamase inhibitor combinations, cephalosporins and carbapenems 
remain effective for UTI treatment, epidemiological trends suggest that emerging resistance 
will be problematic. For example, a study analyzing 11,407 UPEC isolates from community-
acquired infections determined that the prevalence of ESBLs increased from 0.21% in 2003 to 
3% in 2008 (Qi et al., 2010). 
3.1.2 Trimethoprim-sulfamethoxazole (SXT) 
Trimethoprim and sulfamethoxazole are both inhibitors of bacterial folate synthesis, which 
is required for de novo synthesis of thymidine, and therefore DNA synthesis. They are 
administered orally in combination as a 1:5 ratio (SXT). Traditionally a front-line therapy for 
UTIs, their utility has decreased in certain areas due to increasing resistance. In general, 
guidelines state that SXT should be avoided once resistance reaches 15-20%(Gupta et al., 
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2011). The North American Urinary Tract Infection Collaborative Alliance (NAUTICA) study 
analyzed resistance among 1,142 UPEC isolates from outpatients at 40 medical centers and 
found that 21% were resistant to SXT (Zhanel et al., 2006). Similarly, the ARESC study found 
that 29% of UPEC isolates were resistant (Schito et al., 2009). Trimethoprim and 
sulfamethoxazole inhibit dihydrate folate reductase, and dihydropteroate synthetase, 
respectively, and resistance to SXT can be mediated by horizontal transfer of genes encoding 
resistant versions of these enzymes. A study of 305 SXT-resistant UPEC isolates found that 
66% of them encoded a dfr allele encoding a trimethoprim-resistant dihydrate folate 
reductase, and 96% of them had a sul gene encoding a sulfamethoxazole-resistant 
dihydropteroate synthetase. The presence of these genes on integrons and plasmids 
facilitates their spread among bacterial populations (Blahna et al., 2006).  
3.1.3 Fluoroquinolones 
Fluoroquinolones, such as ciprofloxacin and levofloxacin, target bacterial DNA gyrase and 
topoisomerases, enzymes responsible for DNA unwinding during DNA replication. They 
are currently recommended for use as second-line agents for uncomplicated UTIs, and 
front-line therapy for nosocomial UTIs and pyelonephritis (Gupta et al., 2011, Hooton et al., 
2010). Resistance to these agents is largely due to mutations in the gyrA gene encoding the 
gyrase enzyme. (Weigel et al., 2002). The NAUTICA, ARESC and SENTRY studies reported 
UPEC resistance rates of 5-6%, 8% and 11%, respectively (Gordon & Jones, 2003, Schito et al., 
2009, Zhanel et al., 2006). Alarmingly, 25% of UPEC from catheter-associated UTIs are 
fluoroquinolone-resistant (Hidron et al., 2008). The rate of UPEC fluoroquinolone resistance 
appears to be increasing rapidly. Between 1998 and 2005, a four-fold increase in levofloxacin 
prescriptions for UTIs at one medical center was correlated with an increase in resistance 
from 1% to 9% (Johnson et al., 2008). Similarly, a comparison of 2073 nosocomial UPEC 
isolates from 1990-1994 to 3112 isolates from 2000-2004 found that resistance to ciprofloxacin 
increased from 0.9% to 9.8% (Klevens et al., 2008). 
3.1.4 Nitrofurantoin 
Nitrofurantoin is currently recommended as a front-line agent for the treatment of 
community-acquired cystitis (Gupta et al., 2011). The NAUTICA and ARESC studies of 
community-acquired UTIs found only 1.1% and 1.6% of UPEC isolates were nitrofurantoin 
resistant, respectively (Schito et al., 2009, Zhanel et al., 2006). Nitrofurantoin is a pro-drug, 
and when reduced it becomes highly reactive, damaging bacterial DNA. A laboratory study 
identified mutations in the nitroreductase-encoding genes nsfA and nsfB that led to 
resistance. However, the presence of these mutations was associated with poor bacterial 
growth, thus explaining why they are not commonly identified in resistant clinical isolates 
(Sandegren et al., 2008). Nitrofurantoin is often recommended for treatment of pregnant 
patients, as there are concerns about the safety of fluoroquinolones and trimethoprim for 
this population (Macejko & Schaeffer, 2007). However, it is important to note that 
nitrofurantoin is not useful for the treatment of pyelonephritis, and also that many 
uropathogens other than E. coli, such as K. pneumoniae, P. mirabilis and P. aeruginosa, are non-
susceptible. 
3.1.5 Fosfomycin 
Fosfomycin is a broad-spectrum Streptomyces-produced antibiotic that inhibits bacterial cell 
wall synthesis, and is currently recommended as a front-line therapy for community-
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acquired UTIs (Gupta et al., 2011). In vitro studies found high rates of spontaneous 
resistance, but these mutants grew poorly, suggesting that clinical resistance should be rare 
(Nilsson et al., 2003). Indeed, the ARESC study found that only 0.6% of UPEC isolates were 
resistant (Schito et al., 2009). In addition, a recent meta-study analyzing 1657 ESBL-
producing E. coli isolates, most of which were UPEC, found that 97% of them were 
susceptible to fosfomycin (Falagas et al., 2010). Therefore, fosfomycin may have significant 
utility in combating emerging UPEC antibiotic resistance. 
3.1.6 Multi-drug resistant UPEC clones 
In addition to general trends of increasing antibiotic resistance, specific multidrug-
resistant UPEC clones have emerged. A year-long outbreak of O15:K52:H1 E. coli occurred 
in London in 1986-7, causing up to 13% of UTIs in this area during this time period. Most 
of these isolates were resistant to SXT, ampicillin, chloramphenicol, streptomycin and 
tetracycline (Phillips et al., 1988, O'Neill et al., 1990). Analysis of 100 different O15:K2:H1 
clones, isolated over a span of 30 years, revealed that SXT resistance first emerged in this 
lineage in 1986 and fluoroquinolone resistance in 1995 (Olesen et al., 2009). A separate 
group of isolates (also related to O:15:K2:H1), termed clonal Group A (CGA), accounted 
for 50% of SXT-resistant, and 11% of total, cystitis isolates from three geographically 
distinct sites in the US. These isolates typically had similar O (lipopolysaccharide) 
antigens, encoded similar virulence factors and were frequently multidrug resistant 
(Manges et al., 2001). CGA isolates also comprise 34% of SXT-resistant, and 7% of total, 
SXT-resistant pyelonephritis isolates (Johnson et al., 2002). The third major antibiotic-
resistant UPEC clone is O25:H4-ST131, which expresses the CTX-M-15 ESBL rendering it 
resistant to third-generation cephalosporins (Nicolas-Chanoine et al., 2008). These three 
clonal groups accounted for 37% of total UPEC isolates, 44% of SXT-resistant isolates and 
64% of fluoroquinolone-resistant isolates in Canada from 2002-4 (Johnson et al., 2009). 
One-third of ciprofloxacin-resistant UPEC clones in a European study belonged to the 
O15:K2:H1 or O25:H4-ST131 groups (Cagnacci et al., 2008). There are also reports that the 
O25:H4-ST131 lineage has acquired the NDM-1 carbapenemase (Peirano et al., 2011) in 
North America and fosfomycin resistance in Spain (Oteo et al., 2009), indicating that  
this lineage will continue to evolve multi-drug resistance and be a major public health  
issue. 
3.2 Resistance of other uropathogens 
3.2.1 Staphylococcus saprophyticus 
S. saprophyticus is a responsible for 2-6% of uncomplicated UTIs (Kahlmeter, 2003, Schito et 
al., 2009). The ARESC study found resistance rates of 36% for ampicillin and 10% for SXT 
(Schito et al., 2009). An earlier study analyzing isolates from sixteen European countries and 
Canada obtained different results, with only 2% of isolates resistant to ampicillin and none 
resistant to SXT (Kahlmeter, 2003). However, both studies found that >99% of isolates were 
sensitive to amoxicillin-clavulanic acid. 
3.2.2 Klebsiella pneumoniae 
K. pneumoniae is responsible for 1-6% of uncomplicated UTIs (Kahlmeter, 2003, Schito et al., 
2009). In addition to being intrinsically resistant to ampicillin and nitrofurantoin, resistance 
to other antibiotics is very common among these isolates. One study found non-
www.intechopen.com
 
Antibiotic Resistance in Urinary Tract Infections: Current Issues and Future Solutions 
 
199 
susceptibility rates to be 23% for SXT, 21% for cefuroxime (a second-generation 
cephalosporin), 12% for fosfomycin and 6% for ciprofloxacin (Schito et al., 2009). An earlier 
study found a similar resistance pattern, although overall prevalence was lower (Kahlmeter, 
2003). In both studies, 94-99% of isolates were susceptible to ciprofloxacin and 91-96% were 
susceptible to amoxicillin-clavulanic acid. In addition, K. pneumoniae is the cause of 8-11% of 
nosocomial catheter-associated UTIs, and 17-21% of these isolates are resistant to extended-
spectrum cephalosporins and 10% are resistant to carbapenems (Hidron et al., 2008, Gordon 
& Jones, 2003).  
3.2.3 Proteus mirabilis 
P. mirabilis is the cause of 3-5% of uncomplicated UTIs. P. mirabilis is intrinsically non-
susceptible to nitrofurantoin, and also has high levels of non-susceptibility to other common 
UTI therapies—15-38% for SXT, 16-33% for ampicillin and up to 14% for fosfomycin and 
10% for ciprofloxacin. The lowest levels of non-susceptibility were observed for amoxicillin-
clavulanic acid (1-6%) and first (cefadroxil) or second generation (cefuroxime) 
cephalosporins (4-7%) (Schito et al., 2009, Kahlmeter, 2003). P. mirabilis is also the cause of 
5% of nosocomial UTIs and 10%of catheter-associated UTIs (Gordon & Jones, 2003, Hidron 
et al., 2008); however, no extensive studies of antimicrobial resistance for these isolates has 
been performed  
3.2.4 Enterococcus spp. 
Enterococcus spp. are responsible for 13% of nosocomial UTIs. Resistance rates were found to 
be 5% for vancomycin, 12% for ampicillin and ampicillin-clavulanic acid, 37% for SXT and 
50% for ciprofloxacin. Only 1% of isolates were resistant to nitrofurantoin (Gordon & Jones, 
2003). A study of catheter-associated UTIs in the US found that 15% of them were due to 
Enterococcus spp., and these isolates exhibited a much higher rate of vancomycin resistance 
(29%) than nosocomial isolates in general (5%). Most of the resistance was due to E. faecium, 
which was only responsible for 24% of infections but accounted for 72% of vancomycin-
resistant isolates. In addition, 89% of catheter-associated UTI E. faecium isolates were 
ampicillin-resistant. In contrast only 6% of E. faecalis isolates were vancomycin-resistant and 
only 3% were ampicillin resistant (Hidron et al., 2008).  
3.2.5 Pseudomonas aeruginosa 
P. aeruginosa accounts for 8% of nosocomial UTIs, and is intrinsically resistant to ampicillin,, 
ampicillin-clavulanic acid, SXT, nitrofurantoin and cefuroxime. In addition, 59% of isolates 
were ciprofloxacin-resistant (Gordon & Jones, 2003). Ten percent of catheter-associated UTIs 
are caused by P. aeruginosa, and resistance rates were found to be 34% for fluoroquinolones, 
25% for carbapenems (imipenem and meropenem), 11-13% for cephalosporins (cefepime 
and ceftazidime), and 17% for piperacillin (extended-spectrum -lactam), alone or in 
combination with tazobactam (a -lactamase-inhibitor) (Hidron et al., 2008). 
3.3 Newer UTI therapies 
3.3.1 Recently approved therapies 
Doripenem is a broad-spectrum injectable carbapenem -lactam, approved by the FDA in 
2007 for treatment of complicated UTIs, including pyelonephritis. Analysis of 1,772 clinical 
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E. coli isolates (many from complicated UTIs) found that 99.8% of them were susceptible to 
doripenem, including all 30 ESBL-producers (Pillar et al., 2008). Analysis of 6 Phase III 
clinical trials demonstrated that doripenem was as effective as levofloxacin, imipenem, 
meropenem and piperacillin-tazobactam in treatment of patients with complicated UTIs due 
to ciprofloxacin-resistant and ESBL-producing Enterobacteriaceae (largely UPEC) (Kaniga et 
al., 2010). Prulifloxacin is a fluoroquinolone approved for treatment of UTIs in Italy and 
Japan, but not yet approved in the US. A study of 257 patients with complicated UTIs 
showed it was as effective as ciprofloxacin (Carmignani et al., 2005).  
3.3.2 Clinical therapeutic candidates 
ACHN-490 is a next-generation therapeutic belonging to the aminoglycoside family of 
antibiotics that inhibit bacterial protein synthesis. It has demonstrated efficacy in vitro 
against carbapenemase-expressing E. coli and K. pneumoniae (with the exception of NDM-1-
expressing isolates) (Livermore et al., 2011). It is currently being evaluated in a Phase II 
clinical trial for treatment of complicated UTIs. NXL104 is a novel inhibitor of CTX-M -
lactamases (Livermore et al., 2008), and patients are being recruited for a Phase II trial to test 
its efficacy as a combination therapy with ceftaroline (fifth-generation cephalosporin) for the 
treatment of complicated UTIs. There is anecdotal evidence that tigecycline, a glyclcycline 
bacterial protein synthesis inhibitor, may be useful in treating complicated UTIs due to 
multi-drug resistant UPEC (Geerlings et al., 2010). Although tigecycline is not approved for 
treatment of complicated UTIs, it has been suggested that it should be evaluated for this 
indication (Bhattacharya et al., 2009) 
3.3.3 Experimental therapies 
A number of other compounds are still being developed experimentally, and although far 
from the clinic, they provide promise as potential future therapies. One new approach to 
treating UPEC infections is rather than attempting to prevent growth or kill the pathogen, is 
instead to inhibit its virulence properties so that an infection cannot persist (i.e. 
antivirulence therapies). This approach has focused on type 1 fimbriae that are required by 
UPEC to adhere to the bladder epithelium during infection (Hilbert, 2011). The FimH 
adhesin of type 1 fimbriae normally binds mannose, and related compounds, such as butyl 
-D-mannoside, bind with much higher affinity, and therefore may be useful as decoys to 
saturate FimH and impair UPEC adherence to the bladder epithelium (Bouckaert et al., 
2005). Type 1 fimbriae are assembled through the chaperone-usher pathway, and ring-fused 
2-pyridone peptidomimics (i.e. pilicides) impair this pathway, thereby preventing fimbrial 
expression, bacterial adherence and virulence in a mouse model of infection (Pinkner et al., 
2006, Klein et al., 2010). Future studies are necessary to determine if antivirulence therapies 
will be useful in the clinic. 
4. Prevention 
4.1 Cranberry juice 
In addition to improving therapy, another major area of research is the prevention of UTIs. 
As is the case for treatment, both traditional and novel strategies are being evaluated. 
Consumption of cranberry juice is a traditional folk method of UTI prevention and 
treatment. Roughly a dozen studies have been performed examining the ability of cranberry 
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products to prevent UTIs (Raz et al., 2004), but only two were randomized placebo-
controlled studies with significant patient populations (150 women with a history of UTI). 
One study found that daily consumption of cranberry juice concentrate reduced the risk of 
UTI to 16% over a six month period, compared to 36% in the placebo group. A one-year 
study found that <20% of women who consumed cranberry juice or tablets experienced 
UTIs, compared to 32% in the placebo group (Kontiokari et al., 2001, Stothers, 2002). As for 
the mechanism of action, studies have found that cranberry juice extracts inhibited the 
ability UPEC to adhere to vaginal and bladder epithelial cells (Hilbert, 2011). Identification 
of the inhibitory cranberry constituent could facilitate the development of a novel 
antivirulence therapy for UTIs.  
4.2 Vaginal probiotics 
As vaginal and periurethral colonization with UPEC is strongly associated with UTIs 
(Hilbert, 2011), another prevention strategy is to use vaginal probiotics to prevent 
colonization. Small pilot studies have found that vaginal colonization with Lactobacillus spp. 
helps to prevent recurrent UTIs (Bruce & Reid, 1988, Uehara et al., 2006, Reid et al., 1992). A 
Phase I trial on the use of vaginal Lactobacillus suppositories to prevent recurrent UTIs has 
been completed with minimal patient side effects (Czaja et al., 2007), paving the way for 
future trials and the possible use of probiotics clinically to prevent UTIs. 
4.3 Antimicrobial catheters 
Different strategies are used to prevent catheter-associated nosocomial UTIs. One approach 
is the development of catheters coated with silver alloy or nitrofurazone (similar to 
nitrofurantoin) to prevent attachment by uropathogens. A meta-analysis of eight clinical 
trials since 1995 found that the use of these catheters reduced the risk of bacteriuria by up to 
12% when compared to uncoated catheters (Johnson et al., 2006). Another strategy for long-
term catheterization (e.g. patients with neurogenic bladder) is bacterial interference, where 
the bladder is deliberately colonized with an ABU E. coli isolate (ABU 83972) to prevent 
symptomatic infection. A randomized, double-blind placebo-control study found that over a 
period of one year, patients successfully colonized with ABU 83972 had an average 1.6 UTIs, 
whereas the placebo group experienced an average of 3.5 infections (Darouiche et al., 2005).  
4.4 Immuno-stimulation 
Polyvalent mixtures of killed uropathogens have been tested for their ability to prevent 
UTIs. UroVaxom (OM-89) is a lyophilized extract of 18 UPEC strains that is taken orally in 
Europe to prevent recurrent UTIs. It provides immunity to mice in experimental studies 
(Sedelmeier & Bessler, 1995). A meta-analysis of five placebo-controlled double-blind 
studies found that oral consumption of UroVaxom reduced the risk of UTI  by 36% over 6 
months (Naber et al., 2009). These findings were replicated in a large multicenter study (453 
patients) that found a 34% reduction in UTIs over 1 year (Bauer et al., 2005). A related 
product is SolcoUrovac, a vaginal suppository containing lyophilized extract from six UPEC 
strains and one strain each of P. mirabilis, Morganella morganii, K. pneumoniae and E. faecalis. 
A Phase II randomized, double-blind placebo-control trial of 75 women with recurrent UTIs 
over 160 days observed a recurrence rate of 70% for the placebo arm and 27.5% for the 
vaccination plus booster arm of the study (Hopkins et al., 2007). Although these products 
appear useful to prevent recurrent UTIs, they are not vaccines per se as they require frequent 
administration. The clinical trial for UroVaxom had patients take one pill daily for 3 months, 
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no treatment for the next 3 months, then one pill daily for the first 10 days of each of the 
next 3 months followed by another 3 month cessation (Bauer et al., 2005). Similarly, the 
SolcoUrovac trial gave patients one suppository each week for the first three weeks, 
followed by an additional suppository each month for 3 months (Hopkins et al., 2007). 
Therefore, these treatments fall under the category of immuno-stimulation, rather than 
vaccination.  
4.5 Vaccine development 
Development of a UTI vaccine has also been a major research area. Vaccination of 
cynomolgus monkeys with type 1 fimbrial components protected them from UTIs 
(Langermann et al., 2000), as did vaginal immunization with formalin-killed UPEC (Uehling 
et al., 1987). Vaccination of baboons and cynomolgus monkeys with another UPEC adhesin, 
purified P fimbriae, or components thereof, protected them from pyelonephritis (Roberts et 
al., 1989, Roberts et al., 2004). Immuno-correlates for successful vaccination appear to be 
antigen-specific serum IgG, as well as vaginal and urinary antibodies (Hilbert, 2011). 
Although these experimental studies of UPEC vaccination are promising, none of these 
candidates has progressed to clinical testing in humans. 
5. Conclusion 
In summary, rising antibiotic resistance among uropathogens, and especially the emergence 
of multi-drug resistant clonal groups, has provided urgency to the development of novel 
preventative and therapeutic strategies. Some older drugs, such as fosfomycin, may prove to 
be very useful in treating antimicrobial-refractory UTIs, especially those due to ESBL-
producers. Newer drugs, such as the recently approved doripenem, have proven highly 
effective in the clinic to treat complicated UTIs. Research into novel anti-virulence therapies, 
such as inhibiting the production of, or adherence by, UPEC fimbriae is still an early stage 
but holds promise for future development. The use of probiotics to prevent vaginal UPEC 
colonization and the use of an immuno-stimulatory uropathogen extract (SolcoUrovac), are 
currently in clinical trials to determine efficacy in preventing recurrent UTIs. Another 
preventative strategy is vaccination, and experimental vaccines have been developed that 
are effective in preventing UTIs in primates. In summary, a combination of traditional and 
innovative prevention and treatment strategies is being deployed to combat the threat of 
emerging antibiotic resistance among uropathogens. 
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